Recent Updates
Recently added Catalysts

Heart Failure with Decompensation: one US-listed biotech with a clinical-stage programme

Cardiovascular & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$9.2Buniverse median $1.20B
Allocated capital$2.3B$9.2B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank86/299crowding rank 118

Heart Failure with Decompensation is uncontested. Cytokinetics (CYTK) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Omecamtiv Mecarbil in phase 3.

There is no public comparable to price it against. CYTK spreads its $9.2B market cap across 4 indications, so $2.3B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$2.3B of allocated capital sits in Heart Failure with Decompensation, ranking it 86th of 299 indications by the money committed to it.

Companies developing drugs for Heart Failure with Decompensation 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CYTKCytokineticsOmecamtiv MecarbilPhase 31$9.2BNo4 14 Nov 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Heart Failure with Decompensation counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Heart Failure with Decompensation has one competitor and a median of $9.2B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Chronic Heart Failure With Reduced Ejection Fraction1 company · $2.3B · median $9.2BUncontestedCholestatic Liver Disease1 company · $2.2B · median $6.5BUncontestedATTR Amyloidosis2 companies · $2.0B · median $5.7BConcentrated betPostbariatric Hypoglycemia1 company · $1.9B · median $3.8BUncontestedCardiovascular1 company · $1.8B · median $5.5BUncontestedHypertriglyceridemia2 companies · $2.8B · median $10.9BConcentrated betHyperlipidemia1 company · $1.7B · median $12.2BUncontestedDiabetes9 companies · $3.2B · median $401MKnife fight

Heart Failure with Decompensation pipeline questions

Which biotech companies are developing drugs for Heart Failure with Decompensation?

Cytokinetics (CYTK, Omecamtiv Mecarbil, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Heart Failure with Decompensation.

How advanced is the Heart Failure with Decompensation pipeline?

Of the 1 clinical-stage programme in Heart Failure with Decompensation, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Heart Failure with Decompensation?

No. CYTK is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Heart Failure with Decompensation, which is why the indication is classified as uncontested.

When is the next Heart Failure with Decompensation catalyst?

The next dated catalyst in Heart Failure with Decompensation is CYTK on 14 Nov 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map